Amgen stock falls as HSBC downgrade and lower price target weigh on shares
Published on 09/11/2026 at 15:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen stock (ISIN US0311621009) closed at USD 382.47 on Nasdaq on September 10, 2026, down about 2.2 percent for the session as a fresh downgrade and price target cut from HSBC added pressure to the biotechnology group’s shares.Investing.com reported on September 10, 2026 that the stock slipped to USD 382.67 in afternoon trading, reinforcing the negative sentiment heading into September 11, 2026.
HSBC cuts Amgen to Hold and trims price target
According to Investing.com on September 10, 2026, HSBC downgraded Amgen from Buy to Hold and lowered its price target to USD 425 from USD 445, arguing that the shares now trade close to fair value after a period of strong execution and estimate revisions that leave limited near-term upside.
Further detail from Robinhood shows that HSBC’s new target of USD 425 sits roughly 4.5 percent above the September 10, 2026 close of USD 382.47, while the prior USD 445 target had implied around 16.4 percent upside, underscoring how the bank has dialed back its expectations for future share gains.
According to Fintel, the downgrade on September 10, 2026 comes against a backdrop of a broad analyst consensus on Amgen that already skewed toward Hold: in a recommendation period ending September 1, 2026, the stock had accumulated 6 strong buy, 14 buy, 20 hold, 2 sell and 1 strong sell ratings, with an average price target of USD 397.71 that was only modestly above the prevailing market price.
Stock trades below its 52-week high amid pipeline and regulatory overhangs
As Investing.com highlighted on September 10, 2026, Amgen shares were trading well below their 52-week high of USD 447.03, with the USD 382.67 intraday level sitting roughly 14.4 percent under that peak, reflecting the impact of recent sector and company specific headwinds.
The same report pointed to several pressure points weighing on Amgen stock, including lingering uncertainty after a high-profile clinical trial failure in the Lp(a) cholesterol drug class by a competitor, as well as a regulatory setback from a United Kingdom suspension of the company’s autoimmune drug Tavneos, which have together contributed to a more cautious investor stance.
Per data from MarketBeat as of September 10, 2026, Amgen’s Nasdaq traded shares recently changed hands at around USD 381.62, implying a market capitalization of roughly USD 206.32 billion and placing the stock in a 52-week range between USD 269.77 and USD 447.03.
Recent guidance and analyst consensus frame expectations
According to an overview from MarketBeat dated September 11, 2026, Amgen has issued full year 2026 earnings guidance in a range of USD 22.30 to USD 23.50 per share, providing a benchmark against which investors can gauge the impact of current pipeline and regulatory developments on future profitability.
The same MarketBeat data indicates that, based on a broad set of analyst reports, Amgen presently carries an average rating of Hold and an average price target of USD 381.68, with individual targets spanning from USD 200.00 at the low end to USD 460.00 at the high end, suggesting that the consensus view sees only a marginal downside or upside relative to the recent Nasdaq trading level.MarketBeat notes that this translates into a potential downside of about 0.2 percent versus the latest quoted price.
Investor sentiment is thus being guided by a combination of company issued earnings expectations and a broadly neutral analyst stance, with HSBC’s downgrade reinforcing the message that, despite Amgen’s large scale and established portfolio, the room for near term share price appreciation from current levels may be constrained.
Next events and what investors watch now
While no major corporate event is explicitly tied to September 11, 2026 in the available calendars, MarketBeat’s coverage dated September 11, 2026 points out that Amgen’s declared quarterly dividend of USD 2.52 per share remains an important component of the stock’s total return profile, with the payout contributing to a dividend yield of around 2.64 percent based on the recent trading price.MarketBeat lists the stock’s trailing twelve month earnings per share at USD 16.09, implying a price earnings ratio in the mid 20s that investors compare with sector peers when assessing valuation.
For shareholders, the immediate focus on September 11, 2026 is how Amgen stock trades following the HSBC downgrade and the noted sector and regulatory overhangs, with many market participants watching whether the shares can stabilize around the USD 380 level or whether further declines closer to the 52-week midpoint emerge if sentiment stays cautious.
Amgen stock price on Nasdaq as of the last close
As of the close on September 10, 2026, Amgen stock finished at USD 382.47 on Nasdaq, with the session’s move leaving the shares about 14.4 percent below the 52-week high of USD 447.03 and valuing the biotechnology group at just over USD 200 billion.
Key data on Amgen stock
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: AMGN
- Trading venue: Nasdaq
- Price (as of September 10, 2026): 382.47 USD
- Market capitalization: 206.32 billion USD (as of September 10, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: S&P 500
